Pipeline advances outlined by Foghorn Therapeutics in Q3 2026 update

Pipeline advances outlined by Foghorn Therapeutics in Q3 2026 update
Foghorn Q3 2026 pipeline progress

Foghorn Therapeutics issued an update for the third quarter of 2026, citing continued progress across its oncology and immunology and inflammation pipeline.

Key areas of advancement include its oral inflammatory bowel disease program, development of a selective EP300 degrader, and exploration of a novel induced-proximity approach.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.